AI assistant
ADHERIUM LIMITED — Share Issue/Capital Change 2015
Nov 26, 2015
64305_rns_2015-11-26_065a686c-68e6-4f19-a353-7949d1530913.pdf
Share Issue/Capital Change
Open in viewerOpens in your device viewer
Pages (inc this Page) 1
==> picture [191 x 53] intentionally omitted <==
NOVEMBER 27, 2015
ASX Market Announcements ASX Limited Level 4 North Tower, Rialto 525 Collins Street Melbourne VIC 3000
RE: Release of Restricted Securities from Escrow
In connection with the quotation of Adherium Limited’s fully paid ordinary shares ( Shares ) on the Australian Securities Exchange ( ASX ) on 26 August 2015 certain security holders in the Company were required to enter into ASX imposed restriction agreements and/or voluntary escrow agreements. These agreements restricted the relevant security holders from dealing in their securities for periods of up to 24 months from the date of quotation.
In accordance with ASX Listing Rule 3.10A, the Company advises that 146,870 fully paid ordinary shares of the Company will be released from ASX imposed restriction on 14 December 2015.
Application for quotation of these 146,870 fully paid ordinary shares will also be made following their release from restriction.
ASX: ADR
ABN
24 605 352 510
Company Overview
Adherium is a global leader in digital health technologies which address sub optimal medication use in chronic disease.
Directors
Dr J Doug Wilson (Chair) Mr Garth Sutherland (Group CEO) Prof. John Mills Mr Jeremy Curnock Cook Mr Bruce McHarrie Mr Bryan Mogridge
Joint Company Secretaries
Mr Rob Turnbull Ms Bronwyn Le Grice
Registered Office
Level 12, 15 William Street Melbourne VIC 3000 Australia
NZ Office
Kind regards
==> picture [99 x 61] intentionally omitted <==
Rob Turnbull
Level 2, 204 Quay Street Auckland 1010 New Zealand
Investor Relations Contact
Ms Bronwyn Le Grice +61 424 862 600
Joint Company Secretary